Bone marrow-derived mesenchymal stem cells combined with intramuscular injection promote the healing of diabetic foot ulcers: a systematic review and meta-analysis
Quick Take: Intramuscular injection of Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) significantly accelerates healing in chronic diabetic foot ulcers (DFUs).
đź’ˇ Clinical Impact
- Biologic Synergy: BM-MSCs drive healing via paracrine signaling—triggering angiogenesis and modulating the chronic inflammatory environment of the "non-healing" wound.
- Reduced Complexity: The intramuscular delivery route offers a standardized, minimally invasive alternative to traditional surgical grafting or messy topical cell suspensions.
- Limb Salvage Potential: Directly targets the high-risk population where standard of care (SOC) fails, potentially reducing long-term amputation rates.
đź“Š Evidence Breakdown
Evidence Grade: 🟢 8/10 (Strong Signal)
Analysis: This meta-analysis demonstrates a robust statistical benefit for BM-MSC injections over standard wound care. While the efficacy signal is strong, the "Evidence Grade" is tempered by heterogeneity in cell dosing and the lack of standardized "off-the-shelf" protocols.
Note: Long-term durability of the healed tissue remains the primary unanswered clinical question.
đź©ş Practice Recommendation
Promising Adjunctive Therapy: While not yet "Front-Line Standard of Care" due to high cost and specialized processing, clinicians should consider BM-MSC therapy for refractory DFUs that have failed 4+ weeks of aggressive standard management. Monitor for upcoming Phase III data to confirm long-term safety and cost-effectiveness.